Partnership for Detection of Infection by Category B Pathogens

B 类病原体感染检测合作伙伴关系

• 批准号: 7492831
• 负责人: Frances S. Ligler
• 金额: $ 89.5万
• 依托单位: U.S. NAVAL RESEARCH LABORATORY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7492831
• 关键词: Address; Antibodies; Area; Automation; Biological Assay; Biological Markers; Biosensing Techniques; Brucella; Buffers; Campylobacter; Categories; Clinical; Code; Color; Coxiella; Cryptosporidium parvum; Cytometry; Data; Detection; Development; Device or Instrument Development; Devices; Diagnosis; Diagnostic; Elements; Escherichia coli; Exposure to; Giardia lamblia; Goals; Government; Hospitals; Human; Human Resources; Immune; Infection; Infectious Agent; Laboratories; Laboratory Research; Listeria; Magnetism; Measurement; Methodology; Methods; Microspheres; Military Personnel; Monitor; Nucleic Acids; Numbers; Output; Pathogen detection; Patients; Performance; Physicians' Offices; Physiological; Preparation; Process; Proteins; Public Health; Q Fever; Reagent; Research Personnel; Robotics; Running; Salmonella; Sampling; Screening procedure; Sensitivity and Specificity; Shigella; Site; Solid; Sorting - Cell Movement; System; Technology; Testing; Tracer; Training; Universities; Work; base; biodefense; cost; cost effectiveness; high throughput screening; improved; interest; microorganism; nanoparticle; novel; pathogen; pathogen exposure; point of care; rapid technique; response; user-friendly; vaccine efficacy

DESCRIPTION (provided by applicant): The goal of this proposed work is to develop a rapid, automated, multi-analyte diagnostic system based on a novel microflow cytometer for screening exposure to category B pathogens. The resulting device will be portable and field deployable for rapid point-of-care and on-site diagnosis of exposure. The technology can also be used for monitoring efficacy of vaccines as they are developed. Target analytes will include, but are not limited to, Brucella, Coxiella, Salmonella, Campylobacter, E. coli, Shigella, Listeria, Cryptosporidium parvum, Giardia lamblia, and VEE. Development of the proposed diagnostic system will be two pronged, including both assay and device development. First; potential assay formats, using coded microspheres as the solid support, will be investigated, including direct detection of pathogen and indirect identification of pathogen exposure by detecting anti-pathogen antibodies. Optimized assays will be run both in buffer and spiked clinical samples. Candidate capture and tracer reagents, including antibody and non-antibody recognition molecules, will be screened with the goal of reaching physiologically relevant limits-of-detection. Magnetic nanoparticles will be used to pre-concentrate pathogens within the disposable element of the device. Second, expansion of the current microflow cytometry technology will include development and optimization of the 3-color analysis capabilities, automation of the portable system, and inclusion of pathogen sorting capability. The developed system can address of number of the areas of concern for public health including: Assays that demonstrate the highest performance for their detecting pathogens in relevant clinical samples (e.g., sensitivity, specificity, rapidity, ruggedness, ease-of-use and cost-effectiveness). Rapid sample preparation, processing, and target concentration. Improved technologies, methodologies, and reagents for simultaneous testing for multiple targets. Technologies that integrate multiple methods of parallel measurements for detection in the same platform, such as identifying nucleic acids, proteins, and other targets from agents in the same assay. Technologies targeting multiple biomarkers or signature profiles to identify human immune or other physiological responses during infection. Technology adaptable for high throughput, robotic, and automated data output and analyses at minimal cost.

描述（由申请人提供）： 这项工作的目标是开发一种快速，自动化，多分析物诊断系统的基础上，一种新的微流式细胞仪筛选暴露于B类病原体。由此产生的设备将是便携式的，可现场部署，用于快速的护理点和现场诊断暴露。该技术还可用于监测疫苗的有效性。目标分析物将包括但不限于布鲁氏菌、柯克斯氏菌、沙门氏菌、弯曲杆菌、大肠杆菌。大肠杆菌、志贺氏菌、李斯特菌、微小隐孢子虫、贾第鞭毛虫和VEE。 拟议的诊断系统的开发将是双管齐下的，包括检测和设备开发。第一;将研究使用编码微球作为固体支持物的潜在测定形式，包括直接检测病原体和通过检测抗病原体抗体间接鉴定病原体暴露。将在缓冲液和加标临床样品中运行优化的测定。将筛选候选捕获和示踪试剂，包括抗体和非抗体识别分子，目的是达到生理学相关的检测限。磁性纳米颗粒将用于在器械的一次性元件内预浓缩病原体。其次，当前微流式细胞术技术的扩展将包括三色分析能力的开发和优化、便携式系统的自动化以及病原体分选能力的纳入。 所开发的系统可以解决公共卫生方面的一些问题，包括： 在检测相关临床样本中的病原体方面表现出最高性能的检测试剂盒（例如，灵敏度、特异性、快速性、耐用性、易用性和成本效益）。 快速样品制备、处理和目标浓度。 用于同时检测多个靶标的改进技术、方法和试剂。 在同一平台中集成多种并行测量方法进行检测的技术，例如在同一检测中从试剂中识别核酸、蛋白质和其他靶标。 针对多个生物标志物或特征谱的技术，以识别感染期间的人类免疫或其他生理反应。 该技术适用于高通量、机器人和自动化数据输出和分析，成本最低。